subslover
34 분 전
Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence
Average Total Weight Loss of 20% With 15% Increase in Lean Body Mass After 8 Months of Combined Therapy
NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced initial results on the combination of the Allurion Program with low-dose GLP-1 therapy to optimize muscle mass and GLP-1 adherence.
52 patients treated with the Allurion Balloon were started on 0.25mg semaglutide after completing their first month of balloon therapy. The dose of semaglutide was increased to no greater than 1.0mg over the subsequent 6 months. After 8 months of this combination approach, average total body weight loss was 20.3%, and lean body mass increased by 15% from 59.6% to 68.5%. All patients remained adherent to the GLP-1 medication through 8 months.
“I believe combining the Allurion Balloon with low-dose GLP-1 therapy has several advantages,” said Dr. Luigi Flagiello, bariatric surgeon at Clinica Ruesch who oversaw this case series. “These results indicate that a combination approach increases weight loss and that by using lower doses of GLP-1s, patients do not experience as many side effects—including muscle wasting—and have improved adherence. Patients may also be benefiting from two distinct physiological impacts: satiety induction from the balloon and reduced hunger from the GLP-1.”
Previous studies in patients undergoing GLP-1 therapy have demonstrated reductions in lean mass of approximately 40% as a proportion of total weight lost1 and have also shown that 30% of patients discontinue GLP-1 therapy within the first month and 58% discontinue before reaching a clinically meaningful health benefit2, due in part to side effects, dose escalation required for continued weight loss, and cost. Semaglutide dosing is typically increased to 2.4mg, over two times higher than the maximum dose of 1.0mg used in the combination approach.
“Muscle wasting and lack of adherence are significant challenges for GLP-1s, and this initial data suggests that a combination approach that leverages Allurion’s full program—which includes the balloon, our Virtual Care Suite, and our behavior change program—may be a compelling solution,” said Dr. Shantanu Gaur, Founder and CEO of Allurion. “We plan on building upon this promising initial data and are optimistic that this could become a new standard of care for patients who want metabolically healthy weight loss.”
Additional data on the combination approach is being collected as part of this case series and is expected to be presented at upcoming medical meetings.
subslover
2 월 전
Allurion Announces Plans To Optimize Muscle Mass During GLP-1 Therapy In Combination With the Allurion Program
NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced its intention to initiate a clinical study on the combination of the Allurion Program with GLP-1 agonists to improve muscle mass and overall body composition.
Previous studies in patients undergoing GLP-1 therapy have demonstrated reductions in lean mass of approximately 40% as a proportion of total weight lost.1 In contrast, in previous studies, patients treated with the Allurion Balloon in combination with the Allurion Virtual Care Suite have demonstrated strong patient outcomes in which patients lose weight while maintaining, and in some cases, increasing, muscle mass. In one study of 571 patients, patients treated with the Allurion Balloon gained 5.6% in lean body mass while losing 14% of their total body weight over four months.2 In another study of 167 patients, patients treated with the Allurion Balloon experienced a weight reduction of 15.7% with no change in muscle mass.
“Reductions in lean mass and muscle wasting are significant unmet needs in the GLP-1 space, and our early data suggests that we may have a powerful tool in achieving more metabolically healthy weight loss,” said Dr. Shantanu Gaur, Founder and CEO of Allurion. “The goal of our study would be to prove that, by combining the Allurion Balloon and Allurion Virtual Care Suite with GLP-1 therapy, patients can lose significant weight while increasing muscle mass and improving overall body composition. We are optimistic that this would be a significant addition to the possibilities of GLP-1 therapies and, if proven, could become the gold standard for obesity care.”
About Allurion
Allurion is dedicated to ending obesity. The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-lessTM gastric balloon for weight loss, the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers and Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor, and manage weight-loss therapy for patients regardless of their treatment plan. The Allurion Gastric Balloon is an investigational device in the United States.
For more information about Allurion and the Allurion Virtual Care Suite, please visit www.allurion.com.
Forward-Looking Statements
Invest-in-America
9 월 전
ALUR: Glad ya got a CHUCKLE behind my post there, Bro!! (Heck, and regarding incorrigibly FAT Americans --- of all Races, Creeds, Ethnicities, National Origins, & Socio-Political persuasions --- see ME below, just yesterday, simutaneously celebrating the glorious "JUNETEENTH" holiday, and otherwise performing my daily HIP-HOP-CARDIO-FAT-BURNER-WORKOUT routine over here in balmy San Diego, CA!! LIFE IS GOOD --- ain't it, Brutha!!!???)
Topgun21
9 월 전
LMAO investing in America!!! Haha!!
Took position here in $ALUR! ALUR
GREAT NEWS:
America is VERY OBESE!
7/10 kids OBESE
8/10 adults OBESE
No wonder BIG PHARMA loves Americans!!
Their OBESE, and get diabetes, hypertension, strokes, heart attacks etc.
Americans have lots of FAT and it shows!
BOTTOMLINE, here we have a company with amazing results and can lead to BIG BUCKS!
In for nice position here as this can and will go way north here in my opinion!
Trendtrade is right, gym, diet etc .. but based on the MASSIVE OBESITY problem Americans have , this company can make HUNDREDS of millions with their product!
Yo to each and their own, and no theirs no fat shaming in this post.
Just honest assessment with today’s news we have a MASSIVE MOVE inbound due to America’s obesity problem!
All my opinion!
Maverick
$ALUR
Invest-in-America
9 월 전
ALUR: Indeed!! (Hey, Dude, when I first did a cursory reading of their PR today --- NO joking here --- I believed that they had INCREASED the beneficial MUSCLE body mass of patients/subjects who were simply too SKINNY, or otherwise UNDERWEIGHT for persons of their age. I.e., folks of all ages who looked like, 'REFUGEES-FROM-AUSCHWITZ' death camp, circa 1945!!!)
Invest-in-America
9 월 전
ALUR: Hey, Bro, do that!! (Via iHub PM, if you like; and DON'T worry, if I just LOVE your glorious physique, I will NOT ask to MARRY you nor have your CHILD!!! NOT that there's anything WRONG with that --- thanks, Jerry Seinfeld!! I.e., I am NOT a 'FRUITER' --- although I play one on that 'Shit's-Creek' sitcom.)